Ovarian suppression and hormone therapy for breast cancer
Part of Cancer, Skin clinical trials.
This study looks at how well women stick to their hormone therapy plan after breast cancer surgery. The treatment includes ovarian suppression (to lower estrogen) plus endocrine therapy, and the goal is to see how well it works in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were premenopausal (still having periods) at the time of your breast cancer surgery.
- You have newly diagnosed invasive breast cancer at an early stage (I, II, or III).
- Your cancer is hormone receptor–positive (it grows in response to estrogen or progesterone).
- You have had a mastectomy (removal of the breast) and are planning to have ovarian suppression (treatment to stop ovaries from making estrogen).
- You are generally in good health (able to do normal activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks if staying on ovarian function suppression (OFS) therapy beyond 5 years helps prevent breast cancer from coming back. It's for women with early-stage, hormone-sensitive (HR+ HER2-) breast cancer who have already completed 5 years of OFS.
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
This trial tests whether adding a supervised exercise program helps women with hormone-positive breast cancer who are receiving ovarian suppression therapy. It looks at how exercise affects treatment side effects, quality of life, and long-term health.
This trial studies the safety of continuing endocrine therapy with ovarian suppression (for women) after you finish the earlier OVELIA study. It may help doctors confirm that the treatment remains safe for longer-term use.
This trial studies whether ovarian function suppression (a treatment that lowers hormone production from the ovaries) helps women with hormone-receptor positive, HER2-negative breast cancer that has spread to lymph nodes, but who have a low-risk result on a genomic test. It may help reduce breast cancer recurrence while avoiding more intensive treatment for those who are lower risk.
This Phase 3 trial tests whether ongoing treatment with an aromatase inhibitor (a hormone-blocking medicine) after initial chemotherapy can help keep epithelial ovarian/fallopian tube/peritoneal cancer from coming back. It is only for certain tumor types that are hormone-receptor positive (ER+).
Hear when a new Breast Cancer Females trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.